Atlas Trials

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Clinical trial NCT05336721 · TERMINATED

Trial details

NCT number
NCT05336721
Sponsor
Chipscreen Biosciences, Ltd.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple-negative Breast Cancer
Start date
2021-11-05
Primary completion
2024-10-31
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.